• 554 Citations
  • 14 h-Index
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Sandra E. Reznik is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 5 Similar Profiles
Premature Birth Medicine & Life Sciences
Placenta Medicine & Life Sciences
Lipopolysaccharides Medicine & Life Sciences
Endothelin-1 Medicine & Life Sciences
Pregnancy Medicine & Life Sciences
Inflammation Medicine & Life Sciences
Cerebral Malaria Medicine & Life Sciences
Trophoblasts Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 1998 2004

Carboxypeptidase H

Publications 1998 2019

2 Citations (Scopus)

17-α hydroxyprogesterone nanoemulsifying preconcentrate-loaded vaginal tablet: A novel non-invasive approach for the prevention of preterm birth

Patki, M., Giusto, K., Gorasiya, S., Reznik, S. E. & Patel, K., Jul 2019, In : Pharmaceutics. 11, 7, 335.

Research output: Contribution to journalArticle

Open Access
Foams and Jellies Vaginal Creams
Premature Birth

A vaginal nanoformulation of a SphK inhibitor attenuates lipopolysaccharide-induced preterm birth in mice

Giusto, K., Patki, M., Koya, J., Ashby, C. R., Munnangi, S., Patel, K. & Reznik, S. E., Jan 1 2019, In : Nanomedicine. 14, 21, p. 2835-2851 17 p.

Research output: Contribution to journalArticle

Premature Birth
Drug Delivery Systems
Intravaginal Administration

Development of an Arginine Anchored Nanoglobule with Retrograde Trafficking Inhibitor (Retro-2) for the Treatment of an Enterohemorrhagic Escherichia coli Outbreak

Gandhi, T., Patki, M., Kong, J., Koya, J., Yoganathan, S., Reznik, S. & Patel, K., Oct 7 2019, In : Molecular Pharmaceutics. 16, 10, p. 4405-4415 11 p.

Research output: Contribution to journalArticle

Enterohemorrhagic Escherichia coli
Disease Outbreaks
Shiga Toxins
2 Citations (Scopus)
Immune Tolerance
Premature Birth
High Fat Diet
Gene Expression
5 Citations (Scopus)

Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo

De Vera, A. A., Gupta, P., Lei, Z., Liao, D., Narayanan, S., Teng, Q., Reznik, S. E. & Chen, Z. S., Feb 1 2019, In : Cancer Letters. 442, p. 91-103 13 p.

Research output: Contribution to journalArticle

Multiple Drug Resistance
1-Phosphatidylinositol 4-Kinase